Natixis Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.9M | Sell |
|
|||||
|
2025
Q1 | $12.8M | Buy |
|
|||||
|
2024
Q4 | $14.5M | Sell |
|
|||||
|
2024
Q3 | $16.6M | Sell |
|
|||||
|
2024
Q2 | $18.3M | Buy |
|
|||||
|
2024
Q1 | $21.3M | Buy |
|
|||||
|
2023
Q4 | $15.8M | Buy |
|
|||||
|
2023
Q3 | $11.7M | Buy |
|
|||||
|
2023
Q2 | $10.7M | Buy |
|
|||||
|
2023
Q1 | $7.56M | Buy |
|
|||||
|
2022
Q4 | $7.5M | Buy |
|
|||||
|
2022
Q3 | $5.89M | Buy |
|
|||||
|
2022
Q2 | $5.98M | Buy |
|
|||||
|
2022
Q1 | $7.6M | Buy |
|
|||||
|
2021
Q4 | $8.2M | Sell |
|
|||||
|
2021
Q3 | $9.87M | Sell |
|
|||||
|
2021
Q2 | $9.68M | Buy |
|
|||||
|
2021
Q1 | $7.45M | Sell |
|
|||||
|
2020
Q4 | $6.46M | Sell |
|
|||||
|
2020
Q3 | $9.34M | Sell |
|
|||||
|
2020
Q2 | $7.75M | Sell |
|
|||||
|
2020
Q1 | $5.86M | Buy |
|
|||||
|
2019
Q4 | $5.47M | Buy |
|
|||||
|
2019
Q3 | $4.11M | Buy |
|
|||||
|
2019
Q2 | $3.35M | Sell |
|
|||||
|
2019
Q1 | $3.44M | Buy |
|
|||||
|
2018
Q4 | $2.61M | Buy |
|
|||||
|
2018
Q3 | $2.89M | Buy |
|
|||||
|
2018
Q2 | $2.31M | Buy |
|
|||||
|
2018
Q1 | $1.94M | Buy |
|
|||||
|
2017
Q4 | $1.77M | Buy |
|
|||||
|
2017
Q3 | $1.6M | Buy |
|
|||||
|
2014
Q3 | – | Sell |
|
|||||
|
2014
Q2 | $246K | Buy |
|
|||||
|
2014
Q1 | $250K | Buy |
|